KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Dividends Paid - Common: 2019-2025

Historic Dividends Paid - Common for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $34.3 million.

  • Royalty Pharma's Dividends Paid - Common rose 10.52% to $34.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $158.2 million, marking a year-over-year increase of 33.81%. This contributed to the annual value of $125.2 million for FY2024, which is 4.71% up from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's Dividends Paid - Common is $34.3 million, which was down 11.20% from $38.6 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Dividends Paid - Common registered a high of $125.7 million during Q1 2021, and its lowest value of -$230.2 million during Q4 2021.
  • Moreover, its 3-year median value for Dividends Paid - Common was $31.4 million (2024), whereas its average is $33.8 million.
  • The largest annual percentage gain for Royalty Pharma's Dividends Paid - Common in the last 5 years was 114.40% (2022), contrasted with its biggest fall of 72.55% (2022).
  • Over the past 5 years, Royalty Pharma's Dividends Paid - Common (Quarterly) stood at -$230.2 million in 2021, then soared by 114.40% to $33.2 million in 2022, then dropped by 26.13% to $24.5 million in 2023, then grew by 28.42% to $31.4 million in 2024, then rose by 10.52% to $34.3 million in 2025.
  • Its Dividends Paid - Common was $34.3 million in Q3 2025, compared to $38.6 million in Q2 2025 and $53.8 million in Q1 2025.